Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy
Lene V Halvorsen, Ola U Bergland, Camilla L Søraas, Anne Cecilie K Larstorp, Ulla Hjørnholm, Vibeke N Kjær, Marianne K Kringen, Per-Erik Clasen, Renate Haldsrud, Sverre E Kjeldsen, Morten Rostrup, Fadl Elmula M Fadl Elmula, Mimi S Opdal, Aud Høieggen, Lene V Halvorsen, Ola U Bergland, Camilla L Søraas, Anne Cecilie K Larstorp, Ulla Hjørnholm, Vibeke N Kjær, Marianne K Kringen, Per-Erik Clasen, Renate Haldsrud, Sverre E Kjeldsen, Morten Rostrup, Fadl Elmula M Fadl Elmula, Mimi S Opdal, Aud Høieggen
Abstract
Background Measurement of serum concentrations of drugs is a novelty found useful in detecting poor drug adherence in patients taking ≥2 antihypertensive agents. Regarding patients with treatment-resistant hypertension, we previously based our assessment on directly observed therapy. The present study aimed to investigate whether serum drug measurements in patients with resistant hypertension offer additional information regarding drug adherence, beyond that of initial assessment with directly observed therapy. Methods and Results Nineteen patients assumed to have true treatment-resistant hypertension and adherence to antihypertensive drugs based on directly observed therapy were investigated repeatedly through 7 years. Serum concentrations of antihypertensive drugs were measured by ultra-high-performance liquid chromatography-tandem mass spectrometry from blood samples taken at baseline, 6-month, 3-year, and 7-year visits. Cytochrome P450 polymorphisms, self-reported adherence and beliefs about medicine were performed as supplement investigations. Seven patients (37%) were redefined as nonadherent based on their serum concentrations during follow-up. All patients reported high adherence to medications. Nonadherent patients expressed lower necessity and higher concerns regarding intake of antihypertensive medication (P=0.003). Cytochrome P450 polymorphisms affecting metabolism of antihypertensive drugs were found in 16 patients (84%), 21% were poor metabolizers, and none were ultra-rapid metabolizers. Six of 7 patients redefined as nonadherent had cytochrome P450 polymorphisms, however, not explaining the low serum drug concentrations measured in these patients. Conclusions Our data suggest that repeated measurements of serum concentrations of antihypertensive drugs revealed nonadherence in one-third of patients previously evaluated as adherent and treatment resistant by directly observed therapy, thereby improving the accuracy of adherence evaluation. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT01673516.
Keywords: antihypertensive drugs; blood pressure; directly observed therapy; nonadherence; resistant hypertension; serum drug concentrations.
Figures
References
- Eskas PA, Heimark S, Eek Mariampillai J, Larstorp AC, Fadl Elmula FE, Hoieggen A. Adherence to medication and drug monitoring in apparent treatment‐resistant hypertension. Blood Press. 2016;25:199–205. doi: 10.3109/08037051.2015.1121706
- Berra E, Azizi M, Capron A, Høieggen A, Rabbia F, Kjeldsen SE, Staessen JA, Wallemacq P, Persu A. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment‐resistant hypertension. Hypertension. 2016;68:297–306. doi: 10.1161/HYPERTENSIONAHA.116.07464
- Durand CH, Hayes WP, Morrissey JE, Newell JJ, Casey JM, Murphy JA, Molloy GJ. Medication adherence among patients with apparent treatment‐resistant hypertension: systematic review and meta‐analysis. J Hypertens. 2017;35:2346–2357. doi: 10.1097/HJH.0000000000001502
- Hjørnholm UA, Larstorp ACK, Fadl Elmula FEM, Høieggen A, Andersen MH, Kjeldsen SE. Directly observed therapy in hypertension (DOT‐HTN). In: Burnier M, ed. Drug Adherence in Hypertension and Cardiovascular Protection. Springer Nature; 2018:57–85.
- Fadl Elmula FEM, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, et al. Renal sympathetic denervation in patients with treatment‐resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526–532. doi: 10.1161/HYPERTENSIONAHA.113.01452
- Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, Das SR, Halm EA, Kaplan NM, Vongpatanasin W. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63:834–835. doi: 10.1016/j.jacc.2013.10.067
- Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Gulsin GS, Beech A, Marešová V, Topham PS, Stanley A, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042–1048. doi: 10.1161/HYPERTENSIONAHA.117.09631
- de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, van Maarseveen EM, Bots ML, Blankestijn PJ, SYMPATHY Investigators . Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension. 2017;69:678–684. doi: 10.1161/HYPERTENSIONAHA.116.08818
- Eadon MT, Chapman AB. A physiologic approach to the pharmacogenomics of hypertension. Adv Chronic Kidney Dis. 2016;23:91–105. doi: 10.1053/j.ackd.2016.02.003
- Fadl Elmula FEM, Hoffmann P, Larstorp ACK, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment‐resistant hypertension. Hypertension. 2014;63:991–999. doi: 10.1161/HYPERTENSIONAHA.114.03246
- Bergland OU, Søraas CL, Larstorp ACK, Halvorsen LV, Hjørnholm U, Hoffman P, Høieggen A, Fadl Elmula FEM. The randomised Oslo study of renal denervation vs. antihypertensive drug adjustments: efficacy and safety through 7 years of follow‐up. Blood Press. 2021;30:41–50. doi: 10.1080/08037051.2020.1828818
- Bergland OU, Halvorsen LV, Søraas CL, Hjørnholm U, Kjær VN, Rognstad S, Brobak KM, Aune A, Olsen E, Fauchald YM, et al. Detection of nonadherence to antihypertensive treatment by measurements of serum drug concentrations. Hypertension. 2021;78:617–628. doi: 10.1161/HYPERTENSIONAHA.121.17514
- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2014;23:3–16. doi: 10.3109/08037051.2014.868629
- Caudle KE, Sangkuhl K, Whirl‐Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116–124. doi: 10.1111/cts.12692
- Finitsis DJ, Pellowski JA, Huedo‐Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta‐analysis. J Behav Med. 2016;39:1043–1055. doi: 10.1007/s10865-016-9770-6
- Sevilla‐Cazes J, Finkleman BS, Chen J, Brensinger CM, Epstein AE, Streiff MB, Kimmel SE. Association between patient‐reported medication adherence and anticoagulation control. Am J Med. 2017;130:1092–1098.e2. doi: 10.1016/j.amjmed.2017.03.038
- Stavem K, Augestad LA, Kristiansen IS, Rand K. General population norms for the EQ‐5D‐3 L in Norway: comparison of postal and web surveys. Health Qual Life Outcomes. 2018;16:204–214. doi: 10.1186/s12955-018-1029-1
- Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1–24. doi: 10.1080/08870449908407311
- Jónsdóttir H, Friis S, Horne R, Pettersen KI, Reikvam Å, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009;119:78–84. doi: 10.1111/j.1600-0447.2008.01279.x
- Viktil KK, Frøyland H, Rogvin M, Moger TA. Beliefs about medicines among Norwegian outpatients with chronic cardiovascular disease. Eur J Hosp Pharm. 2014;21:118–120. doi: 10.1136/ejhpharm-2013-000346
- Drangsholt SH, Cappelen UW, von der Lippe N, Høieggen A, Os I, Brekke FB. Beliefs about medicines in dialysis patients and after renal transplantation. Hemodial Int. 2019;23:117–125. doi: 10.1111/hdi.12717
- Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555–567. doi: 10.1016/s0022-3999(99)00057-4
- Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, et al. High rates of non‐adherence to antihypertensive treatment revealed by high‐performance liquid chromatography‐tandem mass spectrometry (HP LC‐MS/MS) urine analysis. Heart. 2014;100:855–861. doi: 10.1136/heartjnl-2013-305063
- Mariampillai JE, Eskås PA, Heimark S, Larstorp ACK, Fadl Elmula FEM, Høieggen A, Nortvedt P. Apparent treatment‐resistant hypertension‐patient‐physician relationship and ethical issues. Blood Press. 2017;26:133–138. doi: 10.1080/08037051.2016.1277129
- Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:1–7. doi: 10.3389/fphar.2017.00100
- Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124:1124–1140. doi: 10.1161/CIRCRESAHA.118.313220
- Avataneo V, De Nicolò A, Rabbia F, Perlo E, Burrello J, Berra E, Pappaccogli M, Cusato J, D'Avolio A, Di Perri G, et al. Therapeutic drug monitoring‐guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. Br J Clin Pharmacol. 2018;84:2535–2543. doi: 10.1111/bcp.13706
- Heimark S, Eskås PA, Mariampillai JE, Larstorp ACK, Høieggen A, Fadl Elmula FEM. Tertiary work‐up of apparent treatment‐resistant hypertension. Blood Press. 2016;25:312–318. doi: 10.3109/08037051.2016.1172865
- Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, Morisky DE, Halm EA, Vongpatanasin W. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment‐resistant hypertension. J Am Soc Hypertens. 2015;9:420–426.e2. doi: 10.1016/j.jash.2015.04.004
- Mäenpää H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J. 1987;8:39–43. doi: 10.1093/eurheartj/8.suppl_I.39
- Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, Veelken R, Uder M, Toennes SW. Adherence to antihypertensive medication in treatment‐resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5:e002343. doi: 10.1161/JAHA.115.002343
- Joy MS, Dornbrook‐Lavender K, Blaisdell J, Hilliard T, Boyette T, Hu Y, Hogan SL, Candiani C, Falk RJ, Goldstein JA. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol. 2009;65:947–953. doi: 10.1007/s00228-009-0707-7
- Rognstad S, Søraas CL, Bergland OU, Høieggen A, Strømmen M, Helland A, Opdahl MS. Establishing serum reference ranges for antihypertensive drugs. Ther Drug Monit. 2021;43:116–125. doi: 10.1097/FTD.0000000000000806
- Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284–295.
- Anstensrud AK, Molden E, Haug HJ, Qazi R, Muriq H, Fosshaug LE, Spigset O, Øie E. Impact of genotype‐predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction—a prospective observational study. Eur J Clin Pharmacol. 2020;76:673–683. doi: 10.1007/s00228-020-02832-0
- Whirl‐Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–417. doi: 10.1038/clpt.2012.96
- Blake CM, Kharasch ED, Schwab M, Nagele P. A meta‐analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther. 2013;94:394–399. doi: 10.1038/clpt.2013.96
- Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee TY, Gong Y, Wang D, Schmidt SO, Binkley PF, et al. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype‐derived activity scores. CPT Pharmacometrics Syst Pharmacol. 2020;9:678–685. doi: 10.1002/psp4.12563
- Jukić MM, Smith RL, Molden E, Ingelman‐Sundberg M. Evaluation of the CYP2D6 haplotype activity scores based on metabolic ratios of 4,700 patients treated with three different CYP2D6 substrates. Clin Pharmacol Ther. 2021;110:750–758. doi: 10.1002/cpt.2246
- Burnier M, Vrijens B. Taxonomy of medication adherence: recent developments. In: Burnier M, ed. Drug Adherence in Hypertension and Cardiovascular Protection. Springer Nature; 2018:5–6.
Source: PubMed